|
Results from the follicular lymphoma (FL) outcomes in patients (pts) with relapsed/refractory (R/R) disease treated with systemic therapy in a real-world assessment (FLORA) study. |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Pfizer; Regeneron |
|
|
Honoraria - Abbvie; Bayer; Celgene; Gilead Sciences; Incyte; Janssen; Novartis; Roche |
|
Travel, Accommodations, Expenses - Abbvie; Janssen-Cilag; Kite/Gilead; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Johnson and Johnson (I); Smith & Nephew (I) |
Honoraria - ADC Therapeutics; Takeda |
Consulting or Advisory Role - Novartis; Seagen; SOBI; Takeda |
Speakers' Bureau - Novartis; Seagen; Takeda |
Research Funding - Takeda |
Travel, Accommodations, Expenses - ADC Therapeutics; Takeda |
|
|
Honoraria - Incyte; Janssen; Roche |
|
|
|
Stock and Other Ownership Interests - Regeneron |
|
|
|
Stock and Other Ownership Interests - Regeneron |
|
|
|
Stock and Other Ownership Interests - Regeneron |
|
|
|
Stock and Other Ownership Interests - Regeneron |
|
|
|
Stock and Other Ownership Interests - Regeneron |
Patents, Royalties, Other Intellectual Property - Odronextamab related patents |
|
|
|
Stock and Other Ownership Interests - Regeneron |
|
|
|
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Regeneron |
|
|
Honoraria - Amgen; Gilead Sciences; Incyte; Janssen-Cilag; Novartis; Roche; Takeda |
Consulting or Advisory Role - Gilead Sciences; Incyte; Novartis; Novartis; Roche; Takeda |
Research Funding - Amgen Foundation (Inst); Bristol Myers Squibb Foundation (Inst) |
Travel, Accommodations, Expenses - Gilead Sciences; Incyte; Janssen-Cilag; Roche |